The p53 signaling pathway is the most commonly subverted pathway yet identified in human tumors. At present there is a gamut of biochemical properties and interactions ascribed to p53; however, the transcriptional activity of p53 is still considered to be critical for its tumor suppressive function. The focus of our research continues to be directed at determining how different cell stresses engage p53 and lead to gene expression programs that produce effects ranging from cell cycle arrest, repair, and survival to cell death. It is possible that any stress that produces irreparable or continual DMA damage induces apoptosis or replicative senescence, while other conditions such as repairable levels of damage or transient loss of survival signals produce a reversible p53-mediated cell cycle arrest, repair and survival. During the current grant period we identified several novel target, effector genes of p53 and now we propose to further analyze the proteins they encode in terms of their role in regulating cellular survival versus apoptosis. Further, our recent work has shown that constitutive versus inducible p53 binding to select target genes likely plays a key role in the hierarchy of p53-mediate,d gene regulation; we believe the identification of the mechanism(s) involved in this differential binding merits further investigation. ? ? Based on our findings, we propose to test the following interrelated hypotheses: p53 regulates cellular outcome (viability versus death) after stress through differential transcriptional regulation of target genes that coordinate pathways of growth arrest, repair, and survival versus apoptosis. Further, p53 is constitutively bound to regulatory regions of target genes involved in growth arrest and survival pathways, whereas additional stress-inducible events are required for p53 to bind regulatory regions of target genes involved in apoptosis. The following Specific Aims will test these interrelated hypotheses: (1) To determine the role of novel p53 target gene products involved in regulating cell survival after stress; (2) To determine the role of novel p53 target gene products involved in regulating cell sensitivity to genotoxic stress; and (3) To determine mechanisms involved in dictating constitutive versus stress-inducible binding of p53 to select target genes. The kinetics of in vivo p53 binding and transactivation of target genes under various stress and physiological conditions will be analyzed in parallel with occupancy of promoters by other p53 family member proteins, components of the transcriptional machinery, co-activators, co-repressors, histones, and post-translational modifications of a select set of these proteins. ? ? The importance of understanding p53 regulation and function is underscored by the frequency of p53 mutations in human tumors and the observations that modulating p53 signaling in human cancer cells can induce cell cycle arrest, apoptosis, or chemosensitization depending upon the model system under study. Understanding how p53 signaling mediates these outcomes is expected to eventually translate into therapeutic benefit in the treatment of tumors and thus would have major impact on human health. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA070856-11
Application #
7191744
Study Section
Special Emphasis Panel (ZRG1-ONC-K (04))
Program Officer
Blair, Donald G
Project Start
1997-01-01
Project End
2010-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
11
Fiscal Year
2007
Total Cost
$330,289
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Jovanovi?, Bojana; Mayer, Ingrid A; Mayer, Erica L et al. (2017) A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Clin Cancer Res 23:4035-4045
Marshall, Clayton B; Mays, Deborah J; Beeler, J Scott et al. (2016) p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Cell Rep 14:2289-300
Lehmann, Brian D; Bauer, Joshua A; Schafer, Johanna M et al. (2014) PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 16:406
Chen, Xi; Li, Jiang; Gray, William H et al. (2012) TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform 11:147-56
Lehmann, Brian D; Bauer, Joshua A; Chen, Xi et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-67
Rosenbluth, Jennifer M; Mays, Deborah J; Jiang, Aixiang et al. (2011) Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci U S A 108:2076-81
Eby, Kathryn G; Rosenbluth, Jennifer M; Mays, Deborah J et al. (2010) ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy. Mol Cancer 9:95
Bauer, Joshua A; Chakravarthy, A Bapsi; Rosenbluth, Jennifer M et al. (2010) Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 16:681-90
Bauer, Joshua A; Ye, Fei; Marshall, Clayton B et al. (2010) RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res 12:R41
Adams, Sylvia; Chakravarthy, A Bapsi; Donach, Martin et al. (2010) Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 124:723-32

Showing the most recent 10 out of 51 publications